Akebia Therapeutics(AKBA)
WALTHAM, MABiotechnology
Focus: Akebia Therapeutics is a publicly traded biotech focused on small-molecule treatments for hematology, nephrology, and cardiovascular diseases. The company has one marketed product (Vadadustat for anemia of chronic kidney disease) and a mid-stage pipeline.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Akebia Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Akebia Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Akebia Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$195M
Key Products
GROWTH9.4yr
Lead commercial product and primary revenue driver; HIF-PH inhibitor with 12-year patent runway.
Help build intelligence for Akebia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.